Related Experiment Video
Updated: Jun 19, 2026
08:31
Place and Response Learning in the Open-field Tower Maze
Published on: October 28, 2015
[Alzheimer disease, memory and estrogen].
F Blanc1, P Poisbeau, F Sellal
1Service de Neuropsychologie, Département de Neurologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
Revue Neurologique
|October 20, 2009
Summary
Estrogen
Area of Science:
- Neuroscience
- Endocrinology
- Gerontology
Context:
- Alzheimer's disease (AD) disproportionately affects women, with potential links to post-menopausal estrogen decline.
- Estrogen's role in AD pathogenesis is complex, with conflicting evidence from animal and human studies.
- Previous research indicates estrogen's impact on memory and amyloid deposition, but clinical outcomes vary.
Purpose:
- To review and synthesize existing literature on the effects of estrogen on memory and Alzheimer's disease.
- To explore the paradoxical findings regarding estrogen therapy in women's cognitive health.
- To investigate the potential influence of treatment timing on estrogen's efficacy in AD.
Summary:
- Animal studies suggest estrogen benefits memory and reduces amyloid plaques, while human studies present mixed results.
- Estrogen therapy has shown positive effects on memory in some human studies but a detrimental effect in the large Women's Health Initiative (WHI) trial.
- The review examines estrogen's pro-mnemonic and neuroprotective effects in animal models and human trials.
Impact:
- Findings may clarify the complex relationship between estrogen, memory, and Alzheimer's disease.
- Highlights the need for further research into optimal timing for estrogen interventions.
- Could inform future therapeutic strategies for cognitive decline and AD in women.
More Related Videos
Related Concept Videos
01:23Role of Neurotransmitters in Memory
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is critical for...
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is critical for...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...